Blueprint Medicines (NASDAQ:BPMC) 公布的季度每股亏损为$(0.79)，低于分析师普遍预期的$(0.70)，差距为12.86%。 这较去年同期每股亏损$(1.82)增加了56.59%。 公司报告的季度销售额为1.4637亿美元，超出分析师普遍预期的1.4584亿美元，超出0.36%。 这较去年同期的7196万美元增加了103.41%。

以上内容来自Benzinga Earnings专栏，原文如下：

Blueprint Medicines (NASDAQ:BPMC) reported quarterly losses of $(0.79) per share which missed the analyst consensus estimate of $(0.70) by 12.86 percent. This is a 56.59 percent increase over losses of $(1.82) per share from the same period last year. The company reported quarterly sales of $146.37 million which beat the analyst consensus estimate of $145.84 million by 0.36 percent. This is a 103.41 percent increase over sales of $71.96 million the same period last year.